Jean-Charles Soria: Limiting ecDNA evolution could open impactful new therapeutic horizons
Clinical Research Fellow at Cancer Evolution and Genome Instability Laboratory, was mentioned by
“EcDNA fuels cancer progression: large, mobile circles of DNA in tumors drive high oncogene copies and rapid genetic changes. Their random spread during cell division increases treatment resistance and tumor evolution.
Determining therapeutic vulnerabilities and identifying target compounds to limit ecDNA evolution could open impactful new therapeutic horizons.”
“Origins and impact of extrachromosomal DNA”
Authors: Chris Bailey, Oriol Pich, Kerstin Thol, Mariam Jamal-Hanjani, Charles Swanton et al.
More posts featuring Jean-Charles Soria.
Jean-Charles Soria serves as Amgen’s senior vice president of Oncology within Global Development. He is a medical oncologist and a professor of medicine at Paris-Saclay University. From 2017 to 2019, he was the senior vice president of Research and Development in Oncology at AstraZeneca. Additionally, Soria has authored or co-authored over 670 articles in leading international journals and has been recognized as one of the world’s most influential research scientists.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023